Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of af-001 in differentiated thyroid cancer
jRCT2031250472Phase 1Not yet recruiting
- Sponsor
- Alpha Fusion, Inc.
- Start
- Oct 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label trial of sodium astatide (211At) in papillary thyroid cancer (PTC), follicular carcinoma (FTC) and well-differentiated thyroid cancer (WDTC) (2 cohorts), sponsored by Alpha Fusion, Inc. Primary endpoints: Safety evaluations (Part Ia), Dose-limiting toxicities (DLTs) (Part Ia) and 2 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
sodium astatide (211At)
03
Conditions
papillary thyroid cancer (PTC)follicular carcinoma (FTC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on jRCT2031250472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250472.